Of possible interest to those experiencing tinnitus.
Magda Havas
Auditory perception of
radio-frequency electromagnetic fields
- Document ID:
19820052276 A (82A35811)�File Series: Open Literature
- Report Number: None
- Sales Agency & Price: Issuing Activity -
Copyright
- Authors:
- Chou, C.-K.��Guy, A. W. (Washington,
University)��Galambos, R. (California,
University)
- Journal Title: Acoustical Society of America��Page: vol. 71
- Published: Jun 01, 1982
- Corporate Source:
- (Corporate Source(s) Not Available)
- Pages: 14
- Contract Number: N00014-80-C-0354��USDE-G0080003029
NASA Subject Category:
BEHAVIORAL SCIENCES
- Abstract:
- Absorption of pulsed microwave energy can produce an
auditory sensation in human beings with normal hearing. The phenomenon
manifests itself as a clicking, buzzing, or hissing sound depending on
the modulatory characteristics of the microwaves. While the energy
absorbed and the resulting increment of temperature per pulse at the
threshold of perception are small, most investigators of the phenomenon
believe that it is caused by thermoelastic expansion. In this paper,
literature that describes psychological, behavioral, and physiological
observations as well as physical measurements pertinent to the
microwave-hearing phenomenon is reviewed.
-
- Major Subject Terms:
- AUDITORY PERCEPTION��ELECTROMAGNETIC FIELDS��ENERGY ABSORPTION��MICROWAVE FREQUENCIES�THERMOELASTICITY��THRESHOLDS (PERCEPTION)
- Minor Subject Terms:
- ELECTROMAGNETIC PULSES��HUMAN PERFORMANCE��RADIO FREQUENCIES��RADIOBIOLOGY��THERMAL EXPANSION
- Language Note: English
- Notes:
- Acoustical Society of America, Journal, vol. 71, June 1982,
p. 1321-1334. U.S. Department of Education
- June 1982, p. 1321-1334. U.S. Department of Educatio
�
�
--------
�
�
Please file a comment for the FCC
and FDA joint hearing on "Regulatory Issues Arising from Health Care
Devices that Incorporate Radio Technology Wireless Communications
Networks"
-----
Original Message -----
�
Cindy has kindly provided a template to use as a heading for
your comment containing all the docket numbers and address
information-also below. (I have slightly modified the template to
remove deadline ambiguity.) Comments must be submitted to both the FCC
(FCC Electronic Comment Filing System at:
http://fjallfoss.fcc.gov/ecfs/� and leave the �ET�� off enter 10-120)
and the FDA (http://www.regulations.gov Additional directions below).
They will not share comments with each other. The door has been left
open for those of us highly affected by the proliferation of wireless
technology, but without medical implants to file testimony in the
statement "Additional information and comments deemed pertinent to
this general area of inquiry by any commenter but not specifically
addressed in our listed questions may also be submitted."
Additional Directions for FDA electronic submission of testimony
� Go to regulations.gov
� Click on "Submit a Comment".
� Type FDA-2010-N-0291 in the box under the "Enter Keyword or ID:" and
Click the �Search� button.
� Scroll down the page.� At the lower right corner clock on "Submit a
Comment."
� Fill out the web form information.�
� You can type your Comment directly into the Comment box on the
Right.� If you are submitting your Comment as an attachment, be sure to
state that in the Comment box so that the attachment is properly
handled by the FDA staff.
� Be sure to click on the Attach button to assure that your document is
attached.
� You can click on the "Preview Comment" to double check what you are
submitting.
� Click on "Submit" when you are satisfied with your filing.
Cindy has also provided a draft of her testimony. I have pulled a few
key points from her testimony, paraphrased in my words, that you may
want to address or support or include in your testimony.
The key points are as follows:
- Wireless technology is harmful not only to sensitive electronics
(medical devices), but to human beings themselves.
- Wireless technology is in violation of the Americans with
Disabilities Act. Discuss the restrictions the widespread prevalence of
wireless technology imposes on your life.
- Continued proliferation of wireless technology will increase
healthcare costs. Support with real-life examples if possible.
- Halt deployment of new wireless technologies.
- Wired broad (particularly fiberoptics) should supported to avoid the
need to retrofit and remove dangerous technology.
- The FDA should establish a policy that selects for a public-health
based standard of evidence for judging the science.
- The FCC should formally acknowledge the inadequacy of their thermally
based safety guidelines to protect public health in the face of
continuously increasing microwave radiation exposure. They should then
immediately open a proceeding to update the guidelines to biologically
(not engineering) based conservative standards to establish safe levels
of exposure for the general population during the continuous daily
exposures we now experience.
- The FDA needs to allow people to report health problems caused by
wireless technology, including transmitting utility meters, using their
complaint their Medwatch Program
The DEADLINES for participation are as follows:
July 19 register for meeting, must make a reservation in order to
attend and specifically register if also wish to speak.
July 26-27 meeting with oral presentations
August 16 �deadline to submit comments electronically (comments must be
submitted separately to both FDA and FCC)
Please take a moment to write a brief narrative about your experience
with wireless technology. If you have make and model numbers for
specific equipment that made you sick, please include them. If your
statement is more general in nature, that is fine. Detailed referencing
of your experience with scientific references is not required or
necessary. Others will provide that information. Your testimony is
necessary to help support them by providing personal experiential
evidence. Make your piece as brief and powerful as possible while
providing all essential information. Do keep in mind that this will be
a public document. If you have one, filing a copy of a supporting
letter from a health care provider would add power. I have attached a
copy of a write-up that I did to help a few others talk to their health
care providers about radiofrequency sickness and transmitting utility
meters. This may help them to understand the seriousness of the problem
and make them more willing to write you a letter whether you are able
to get it in time to file or for later use. Those who are concerned
about the long-term health effects of wireless technology (microwave
radiation exposure) should submit testimony outlining their reasons for
concern.
Please take the time to submit testimony. If enough people do so there
is a real chance of significant positive change.
Thank you for your help and work on this issue. We can't do it without
you.
Please distribute this widely.
Catherine
Critical Deadline: Letter to FDA/FCC on wireless interference
with medical implants/critical care equipment
From: Sage Associates <sa...@silcom.com>
Date: July 2, 2010 2:57:58 PM CDT
Dear friends,
Can you take a moment and email a letter of comment to the
FDA/FCC hearing officers that will be taking testimony at
a July hearing in Washington DC on the issue of RF wireless problems
created for people with medical implants, and the effect of wireless
medical devices on people?
This can address smart meters and wireless broadband.. since the 20
million Americans with disabilities (medical implants) are at the heart
of
the issue with RF interference... this opens a big door.
Short is fine.
The file below has a template for who to direct the letter to, and
the email addresses to send it. Ignore the June 25th deadline (it was
ridiculously short, and the agencies have indicated they will allow
letters now).
I will also send the entire announcement from FDA/FCC, if you want more
detail.
Please know that this is the open-door we wanted - to tell federal
agencies with
jurisdiction over the proliferation of wireless - that there are
problems now with
RF wireless in daily life that affect people with medical implants, and
who depend
on critical care medical equipment. The local Starbucks, security gates
in stores,
RFID scanners used in reprogramming pacemakers and DSBs, and many kinds
of existing RF sources. Perhaps more importantly, we have to say why it
will
be aggravated by the rollout of new wireless broadband and wireless
smart meters.
Such massively increased RF exposures that are involuntary, are
invisible, potentially
dangerous when cumulative, etc must be part of the conversation.
That Pres. Obama would issue a memo supporting the sale of new wireless
spectrum
to industry to facilitate heavier loads of RF in the atmosphere to
accommodate data
transmission (cell phone video, music, etc) is outrageous. There has
been no
cumulative evaluation of all sources of RF we already live with, let
alone the massive
increase in RF expected with these two new sources.
Please, write your thoughts, your experiences.
Thanks - and copy us with your letter please. <sa...@silcom.com>
My draft (not final) is attached.
I've also attached Gary Ohloeft's letter (the first I've received).
Cindy Sage
From: Cheryl King [Chery...@fcc.gov]
Sent: Tuesday, June 15, 2010 9:56 AM
Subject: FW: FCC AND FDA TO HOLD PUBLIC MEETING ON REGULATORY
ISSUES ARISING FROM HEALTH CARE DEVICES THAT INCORPORATE RADIO
TECHNOLOGY WIRELESS COMMUNICATIONS NETWORKS; COMMENTS SOUGHT.
�Colleagues:� FYI
Released:� 06/15/2010.� FEDERAL COMMUNICATIONS COMMISSION (FCC) AND
FOOD AND DRUG ADMINISTRATION (FDA) TO HOLD PUBLIC MEETING ON REGULATORY
ISSUES ARISING FROM HEALTH CARE DEVICES THAT INCORPORATE RADIO
TECHNOLOGY WIRELESS COMMUNICATIONS NETWORKS; COMMENTS SOUGHT. (DA No.�
10-1071). (Dkt No 10-120 ). Comments Due:� 06/25/2010.� OET . News
Media Contact: Bruce Romano at (202) 418-2470, email:
Bruce....@fcc.gov, FDA Contact: Bakul Patel at (301) 796-5528,
email: Bakul...@fda.hhs.gov
____________________________________________________________________________________
�����������������������������������������������������������������������������������������������������������������������
����������� DA 10-1071
�����������������������������������������������������������������������������������������������
��� ���������Released: �June 15, 2010
�
Federal Communications Commission (FCC) and Food and Drug
Administration (FDA) to Hold Public Meeting on Regulatory Issues
Arising from Health Care Devices that Incorporate Radio Technology
Wireless Communications Networks;
Comments Sought
����������������������������������������������������������� FCC
Docket No. ET 10-120
����������������������������������������������������������� FDA Docket
No. FDA-2010-N-0291
�
Comment Date: June 25, 2010
The Federal Communications Commission (FCC) and Food and Drug
Administration (FDA) are seeking comment on converged communications
and health care devices impact on regulation.� A public meeting
to discuss topics related to this issue is scheduled for July
26 and 27, 2010.
����������� The Food and Drug Administration (FDA) and the Federal
Communications Commission (FCC) are jointly sponsoring a public meeting
entitled: �Enabling the Convergence of Communications and Medical
Systems: Ways to Update Regulatory and Information Processes.� The
purpose of this meeting is to gather input from the medical,
telecommunications, and device manufacturing industries; practitioners,
patients, and other users; and other relevant stakeholders to
identify the challenges and risks posed by the proliferation of new
sophisticated medical implants and other devices that utilize radio
communications to effectuate their function, as well as challenges and
risks posed by the development and integration of broadband
communications technology with health care devices and applications.�
The information gathered will be used to enhance the coordination
between FDA and FCC for such devices and applications, and clarify and
delineate the respective areas of expertise and jurisdiction between
the agencies.� This information will simplify and expedite the
introduction of new and important medical technologies and techniques
while maintaining safety and efficacy levels appropriate to the various
technologies and devices. �FDA and FCC are seeking input on these
topics and request information and comments responsive to a number of
specific questions related below.� Additional information and
comments deemed pertinent to this general area of inquiry by any
commenter but not specifically addressed in our listed questions may
also be submitted.� While the general format for this meeting is
outlined in this document, the details will be further informed by the
comments received, and a final agenda will be published on the Internet
in the future.
Date and Time:� The public meeting is scheduled for July 26 and 27,
2010, from 8:00 a.m. to 5:30 p.m. Persons interested in attending
and/or participating in the meeting must register by 5 p.m. on July 19,
2010.� Submit written or electronic comments by June 25, 2010, 5:00
p.m. EDT. (August 16 �deadline to submit written or
electronic comments. I don't know if this is a change or if the June 25
Deadline always applied only to comments on agenda.)
Location:� The public meeting will be held at the FCC Commission
Meeting Room, 445 12th St., SW, Washington, DC
Contact Persons:
FDA:��� Bakul Patel, bakul...@fda.hhs.gov, 301-796-5528
Food and Drug Administration, Center for Devices and Radiological Health
10903 New Hampshire Avenue, Bldg. 66, rm. 3543, Silver Spring, MD 20993
�FCC: Bruce Romano, bruce....@fcc.gov, 202-418-2470
Federal Communications Commmission, room 7-C140
445 12th St., SW, Washington, DC 20554
�
Registration and Requests for Oral Presentations:� The meeting is
open to the public.� Registration requests must be received by 5
p.m. on July 19, 2010.� Interested persons may register by
e-mailingfc...@fcc.gov. Registrants must provide the following
information: (1) name, (2) title, (3) company or organization, (4)
mailing address, (5) telephone number, and (6) e-mail address.�
Registrants will receive confirmation once they have been accepted.�
Persons interested in attending the meeting are encouraged to register
as registrants will have seating priority in order of registration and
can be best assured of receiving information by e-mail regarding any
changes that may occur in meeting particulars.� Also, registration will
be required for all speakers.� Overflow rooms with closed circuit video
monitors will be provided as needed to accommodate the public.� FDA and
FCC may limit the number of registrants from each organization based on
space limitations.
If you wish to make an oral presentation during any of the open comment
sessions at the meeting, you must indicate this at the time of
registration.� FDA and FCC have included specific questions for comment
in section III of this document, Questions for Comment.� You should
also identify which discussion topic you wish to address in your
presentation.� In order to keep each open comment session focused on
the topic at hand, each oral presentation should address only the topic
specified for that session.� FDA and FCC will do their best to
accommodate requests to speak.� Individuals and organizations with
common interests are urged to consolidate or coordinate their
presentations, and to request time for a joint presentation.� FDA and
FCC will determine the amount of time allotted to each presenter and
the approximate time that each oral presentation is scheduled to begin.
����������� Reasonable accommodations for people with disabilities are
available upon request.� The request should include a detailed
description of the accommodation needed and contact information.��
Please provide as much advance notice as possible; last minute requests
will be accepted, but may not be possible to fulfill.� Send an email to
fcc...@fcc.gov or call the Consumer and Governmental Affairs Bureau at
202-418-0530 (voice), 202-418-0432 (TTY).
Comments: FDA and FCC are holding this public meeting to gather
information on a number of questions regarding regulatory challenges
and safety for patients and other users of medical devices that include
radio elements and of systems that can be tied into broadband
communication networks. �The deadline for submitting comments related
to this public meeting is June 25, 2010, 5:00 p.m. EDT. �
Any interested persons may submit electronic comments to
http://www.regulations.gov, or written comments to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852 and to the Federal
Communications Commission, Office of the Secretary, 445 12th Street,
SW, Room TW-A235, Washington, DC 20554 . Submit one paper copy of
mailed comments if you are submitting to FDA and two paper copies of
mailed comments if you are submitting to FCC, except that individuals
may submit one paper copy to each address. �Identify comments with the
docket numbers found in the heading of this document. �In addition,
when responding to specific questions as outlined in this document,
please identify the question you are addressing. Received comments are
available at all times via the Federal eRulemaking
Portal:�http://www.regulations.gov. �They also may be seen in FDA�s
Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday or at the� Federal Communications Commission, Reference
Information Center, CY-A257, Monday through Thursday between the hours
of 8 a.m. and 4:30 p.m. and on Fridays between the hours of 8 a.m. and
12:00 Noon.
SUPPLEMENTARY INFORMATION:
I.��������� Background
There have been significant developments in recent years in medical and
health care devices using radio technology to monitor various body
functions and conditions, including critical elements, and to deliver
treatment and therapy.� There has also been an increasing proliferation
of devices using established commercial communications networks,
including those providing Internet connectivity, to communicate with
care providers.� Mobile devices like smartphones and personal digital
assistants (PDAs) are transforming the transmission of information used
by physicians to help manage patient care, including communication
networks to relay information for patient health monitoring and
decision support.
Examples of the latest implant or body-worn monitoring, therapeutic,
and treatment technologies include blood glucose monitors and automated
insulin pumps, heart monitors, pacemakers, defibrillators, and neural
pathway replacements that stimulate muscle movement.
Examples of devices and applications that use commercial communications
networks and represent the convergence of communications and medicine
include a smartphone application that displays real-time fetal
heartbeat and maternal contraction data allowing obstetricians to track
a mother�s labor and wearable wireless patch-like sensors that transmit
health data over commercial wireless networks to practitioners,
caregivers and patients.
These and other products cover a broad range of health care solutions.
At one end, general-purpose communications devices such as smartphones,
wireless routers and certain video-conferencing equipment are regulated
by FCC.� At the other end, medical devices that critically monitor
patient health or provide treatment or therapy are regulated by FDA.�
Devices that do provide critical care and also use communications, such
as life-critical wireless devices like remotely controlled drug-release
mechanisms, are regulated by both agencies.� In addition, device
applications that would not be governed by FCC but transmit over
wireless networks might warrant FDA oversight, while FCC might have
better capability to assess the reliability of their communications
capability.
FCC and FDA recognize the need to work with all stakeholders to
identify pathways and strive to improve processes that will help
continue to spur innovation in these areas while maintaining safety and
effectiveness and promoting public health.�
II.�������� Public Meeting
The objective of this meeting is to gather information and to better
understand issues and perspectives from various stakeholders so the
agencies can identify potential areas where each agency�s jurisdiction
can be identified and clarified for affected parties, collection and
assessment of each agency�s respectively appropriate information can be
improved, expertise can be shared, and regulatory approval can be
coordinated and simplified.� These concerns relate both to devices
operating on designated frequencies and to convergent medical device
and information technology, as described previously.� This includes
challenges faced by manufacturers and innovators in ensuring compliance
with various regulatory requirements and risks associated with medical
device systems using spectrum shared by other medical devices, using
spectrum shared by other types of devices and services, and using
broadband communication capabilities.
In advance of the meeting, additional information, including a meeting
agenda with a speakers� schedule for each session, will be made
available on the Internet. This information will be placed on file in
the public docket (docket number found in brackets in the heading of
this document), which is available at http://www.regulations.gov and in
the FCC and FDA public reference rooms listed previously. This
information will also be available at
http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm
(select the appropriate meeting from the list), and from
http://www.fcc.gov/workshops (select the appropriate meeting from the
list).
III.������� Questions for Comment
FDA and FCC are planning to focus the public meeting on the
following topics:
� .��� Data integrity and reliability issues arising from the use of
allocated spectrum, the use of unlicensed devices, and the use of
commercial networks and applications, and needs, uses, and risks for
�medical-grade� wireless technology and communications.
� .��� Medical device and system security issues � inadvertent and
intentional intrusion � nonfunction and malfunction.
� .��� Trends in medical devices using allocated spectrum and using
unlicensed operation, and medical devices and applications using
commercial networks. Consideration of various wireless networking
scenarios and use cases.
� .��� Risks Management:
� .��������������������� The need to define levels of �criticality� of
device function that can be used for determining reliability
requirements.
� .��������������������� Environmental factors and delivery setting �
hospitals, users, clinics, home, travel, etc.
� .��� Views on current FDA and FCC regulatory requirements:
� .��������������������� Relationship between FDA approval/clearance
and FCC certification of applications, post market and compliance
requirements.
�
Each of the previous topics will cover
1.����� Defining topics and scope;
2.����� Identifying the needs, goals and stakeholders; and
3.����� Recommendations.
FCC and FDA are seeking comments on the topics and soliciting
suggestions on alternate or additional topics that commenters deem
closely related.� All comments and suggestions will be considered
with the constraint of completing the workshop in no more than two
days.� To be considered, topics proposed must be relevant to the
objective and intent of the workshop.
IV.������� Transcripts
Please be advised that as soon as a transcript is available, it will be
accessible at the Federal eRulemaking Portal:�
�http://www.regulations.gov.� Transcripts of the public meeting may be
requested in writing from the Freedom of Information Office (HFI�35),
Food and Drug Administration, 5600 Fishers Lane, rm. 6�30, Rockville,
MD 20857, approximately 15 working days after the public meeting at a
cost of 10 cents per page. Transcripts may also be viewed at the
Federal Communications Commission, Reference Information Center, Monday
through Thursday, between the hours of 8 a.m. and 4:30 p.m. and on
Fridays between the hours of 8 a.m. and 12:00 Noon.
Examples of the latest implant or body-worn monitoring, therapeutic,
and treatment technologies include blood glucose monitors and automated
insulin pumps, heart monitors, pacemakers, defibrillators, and neural
pathway replacements that stimulate muscle movement.
Examples of devices and applications that use commercial communications
networks and represent the convergence of communications and medicine
include a smartphone application that displays real-time fetal
heartbeat and maternal contraction data allowing obstetricians to track
a mother�s labor and wearable wireless patch-like sensors that transmit
health data over commercial wireless networks to practitioners,
caregivers and patients.
These and other products cover a broad range of health care solutions.
At one end, general-purpose communications devices such as smartphones,
wireless routers and certain video-conferencing equipment are regulated
by FCC.� At the other end, medical devices that critically monitor
patient health or provide treatment or therapy are regulated by FDA.�
Devices that do provide critical care and also use communications, such
as life-critical wireless devices like remotely controlled drug-release
mechanisms, are regulated by both agencies.� In addition, device
applications that would not be governed by FCC but transmit over
wireless networks might warrant FDA oversight, while FCC might have
better capability to assess the reliability of their communications
capability.
FCC and FDA recognize the need to work with all stakeholders to
identify pathways and strive to improve processes that will help
continue to spur innovation in these areas while maintaining safety and
effectiveness and promoting public health.
Informant: Martin Weatherall
[
http://www.buergerwelle.de:8080/helma/twoday/bwnews/search?q=electromagnetic+field
http://omega.twoday.net/search?q=electromagnetic+field
http://www.buergerwelle.de:8080/helma/twoday/bwnews/search?q=radiofrequency
http://omega.twoday.net/search?q=radiofrequency
http://www.buergerwelle.de:8080/helma/twoday/bwnews/search?q=microwaves
http://omega.twoday.net/search?q=microwaves
http://www.buergerwelle.de:8080/helma/twoday/bwnews/search?q=microwave+hearing
http://omega.twoday.net/search?q=microwave+hearing
http://www.buergerwelle.de:8080/helma/twoday/bwnews/search?q=auditory
http://omega.twoday.net/search?q=auditory
http://www.buergerwelle.de:8080/helma/twoday/bwnews/search?q=tinnitus
http://omega.twoday.net/search?q=tinnitus
http://www.buergerwelle.de:8080/helma/twoday/bwnews/search?q=Magda+Havas
http://omega.twoday.net/search?q=Magda+Havas
http://www.buergerwelle.de:8080/helma/twoday/bwnews/search?q=Cindy+Sage
http://omega.twoday.net/search?q=Cindy+Sage
]